Abstract

Digital analysis of pathology whole-slide images is fast becoming a game changer in cancer diagnosis and treatment. Specifically, deep learning methods have shown great potential to support pathology analysis, with recent studies identifying molecular traits that were not previously recognized in pathology H&E whole-slide images. Simultaneous to these developments, it is becoming increasingly evident that tumor heterogeneity is an important determinant of cancer prognosis and susceptibility to treatment, and should therefore play a role in the evolving practices of matching treatment protocols to patients. State of the art diagnostic procedures, however, do not provide automated methods for characterizing and/or quantifying tumor heterogeneity, certainly not in a spatial context. Further, existing methods for analyzing pathology whole-slide images from bulk measurements require many training samples and complex pipelines. Our work addresses these two challenges. First, we train deep learning models to spatially resolve bulk mRNA and miRNA expression levels on pathology whole-slide images (WSIs). Our models reach up to 0.95 AUC on held-out test sets from two cancer cohorts using a simple training pipeline and a small number of training samples. Using the inferred gene expression levels, we further develop a method to spatially characterize tumor heterogeneity. Specifically, we produce tumor molecular cartographies and heterogeneity maps of WSIs and formulate a heterogeneity index (HTI) that quantifies the level of heterogeneity within these maps. Applying our methods to breast and lung cancer slides, we show a significant statistical link between heterogeneity and survival. Our methods potentially open a new and accessible approach to investigating tumor heterogeneity and other spatial molecular properties and their link to clinical characteristics, including treatment susceptibility and survival.

Details

Title
Spatial transcriptomics inferred from pathology whole-slide images links tumor heterogeneity to survival in breast and lung cancer
Author
Levy-Jurgenson Alona 1 ; Tekpli Xavier 2 ; Kristensen, Vessela N 3 ; Zohar, Yakhini 4 

 Technion - Israel Institute of Technology, Department of Computer Science, Haifa, Israel (GRID:grid.6451.6) (ISNI:0000000121102151) 
 University of Oslo and Oslo University Hospital, Department of Medical Genetics, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); Oslo University Hospital, Department of Cancer Genetics, Institute for Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485) 
 University of Oslo and Oslo University Hospital, Department of Medical Genetics, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); Oslo University Hospital, Department of Cancer Genetics, Institute for Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); Akershus University Hospital, Division of Medicine, Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Lørenskog, Norway (GRID:grid.411279.8) (ISNI:0000 0000 9637 455X) 
 Technion - Israel Institute of Technology, Department of Computer Science, Haifa, Israel (GRID:grid.6451.6) (ISNI:0000000121102151); Arazi School of Computer Science, Interdisciplinary Center, Herzliya, Israel (GRID:grid.21166.32) (ISNI:0000 0004 0604 8611) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2471530555
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.